Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T21:18:19.699Z.
Calculation as of: 2026-10-06T21:18:19.699Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bc1f4c18f19876ab16fbc38bb33c2f59d02ebf5b777874ee4386cd5e587f8fe3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$634.30M
EV/EBIT Ratio
12.55x
TTM Avg
14.57x
3Y Avg
14.57x
5Y Avg
18.55x
Market Cap
$597.55M
EV/EBIT Ratio
3.88x
TTM Avg
7.80x
3Y Avg
8.99x
5Y Avg
8.51x
Market Cap
$596.01M
EV/EBIT Ratio
N/A
TTM Avg
596.45x
3Y Avg
263.81x
5Y Avg
279.32x
Market Cap
$584.48M
EV/EBIT Ratio
N/A
TTM Avg
2.85x
3Y Avg
52.42x
5Y Avg
52.42x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SOPHiA GENETICS S.A. (SOPH) | $619.15M | N/A | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $611.57M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $630.63M | N/A | N/A | N/A | N/A |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | N/A | N/A | N/A | N/A |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $634.30M | 12.55x | 14.57x | 14.57x | 18.55x |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | N/A | N/A | N/A | N/A |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $597.55M | 3.88x | 7.80x | 8.99x | 8.51x |
| AngioDynamics, Inc. (ANGO)vs › | $596.01M | N/A | 596.45x | 263.81x | 279.32x |
| Fulgent Genetics, Inc. (FLGT)vs › | $584.48M | N/A | 2.85x | 52.42x | 52.42x |
| OrthoPediatrics Corp. (KIDS)vs › | $583.31M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
